Article Details
Retrieved on: 2024-05-01 20:29:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Pfizer's financial gains through cost-cutting, Seagen's acquisition, and strong sales of its COVID treatments, despite competition in the RSV vaccine market, particularly from GSK's Arexvy.
Article found on: m.economictimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here